M. J. Mooren

发表

Cardiovascular protection by postmenopausal hormone replacement therapy -- the point of lower oestrogen dosages.

M. J. Mooren, MJ van der Mooren, 2001 .

Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo‐controlled study

P. Kenemans, T. Teerlink, M. J. Mooren, 2006, Journal of internal medicine.

M. Rees, T. Mander (Eds.), Managing the Menopause Without Oestrogen, 101 pp., Chapters 16, ISBN 1-85315-592-6.

M. J. Mooren, 2005 .

Serum CA 125 concentrations in women of different ages, hormonal statuses, orclinical conditions

A. Verbeek, L. Massuger, Chris M. G. Thomas, 1997 .

Homocysteine in Postmenopausal Women and the Importance of Hormone Replacement Therapy

V. Mijatovic, M. J. Mooren, 2001, Clinical chemistry and laboratory medicine.

Oral 17β-Estradiol Continuously Combined with Dydrogesterone Lowers Serum Lipoprotein(a) Concentrations in Healthy Postmenopausal Women1

P. Kenemans, J. C. Netelenbos, G. Kamp, 1997 .

Plasma homocysteine and menopausal status **

H. Blom, G. Boers, Christopher M Thomas, 1995, European journal of clinical investigation.

Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women

H. Blom, T. Eskes, M. Wouters, 1994, European journal of clinical investigation.

Intranasal horm one therapy Part II Intranasal hormone therapy

P. Kenemans, P. Weijer, M. J. Mooren, 2007 .

Hormone replacement therapy increases serum 1,25-dihydroxyvitamin D: A 2-year prospective study

T. Benraad, M. J. Mooren, M. J. van der Mooren, 1994, Calcified Tissue International.

Homocysteine concentrations may decrease during postmenopausal hormone replacement therapy

H. Blom, T. Eskes, M. Wouters, 1995 .

Hormone replacement therapy: metabolic and endometrial changes, and the role of progestogens

M. J. Mooren, 1994 .

Mammographic changes in postmenopausal women on hormonal replacement therapy

J. Hendriks, M. J. Mooren, R. Rolland, 2007, European Radiology.

Hormone Replacement Therapy, Selective Estrogen Receptor Modulators, and Tissue-Specific Compounds

T. Vogelvang, V. Mijatovic, M. J. Mooren, 2004, Treatments in endocrinology.

Hyperhomocysteinemia: A risk factor for cardiovascular disease … Influence of sex hormones on homocysteine metabolism

H. Blom, M. J. Mooren, 1996 .

New emerging risk factors for cardiovascular disease: their relation with menopause and hormone therapy

M. J. Mooren, R. Smolders, 2000 .

Gonadotropin‐releasing hormone agonist plus ‘add‐back’ for the treatment of endometriosis. A prospective, randomized, placebo controlled, double blind trial

M. J. Mooren, H. Franke, P. V. D. Weijer, 2000 .

A 2-year study on the beneficial effects of 17 beta-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone.

G. Borm, P. Demacker, M. J. Mooren, 1993, European journal of obstetrics, gynecology, and reproductive biology.

Plasma homocysteine is weakly correlated with plasma endothelin and von Willebrand factor but not with endothelium-dependent vasodilatation in healthy postmenopausal women.

C. Stehouwer, C. Schalkwijk, C. Netelenbos, 1999, Clinical chemistry.

Effects of Quarterly Hormone Replacement Therapy on Climacteric Symptoms, Endometrial Safety, and Lipoproteins

A. Hanselaar, P. Demacker, M. J. Mooren, 1997 .

The effect of sequential three‐monthly hormone replacement therapy on several cardiovascular risk estimators in post‐menopausal women

H. Blom, P. Demacker, M. J. Mooren, 1997, Fertility and sterility.

F179 The influence of postmenopausal oestradiol-dydrogesterone therapy on blood pressure

M. J. Mooren, 1996 .

Hormone replacement therapy and cardioprotection: basic concepts and clinical considerations.

P. Kenemans, A. Pines, V. Mijatovic, 1997, European journal of obstetrics, gynecology, and reproductive biology.

Estrogens ,homocysteine ,vasodilatation and menopause: basic mechanisms ,interactions and clinical implications

P. Sipkema, P. Kenemans, M. J. Mooren, 2003, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Changes in the low-density lipoprotein profile during 17 beta-estradiol-dydrogesterone therapy in postmenopausal women.

J. Graaf, P. Demacker, J. de Graaf, 1994, Metabolism: clinical and experimental.

Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease.

C. Stehouwer, W. M. van Baal, V. Mijatovic, 1998, Maturitas.

Hormone replacement therapy and plasma homocysteine levels.

W. M. van Baal, P. Kenemans, T. Teerlink, 1999, Obstetrics and gynecology.

Ambulatory--not office--blood pressures decline during hormone replacement therapy in healthy postmenopausal women.

F. V. van Ittersum, A. Donker, C. Stehouwer, 1998, American journal of hypertension.

Effects of hormone replacement therapy on blood platelets

C. Stehouwer, W. M. van Baal, P. Kenemans, 2002, European journal of clinical investigation.

Best Practise and Research Clinical Endocrinology and Metabolism. The Menopause and HRT

M. J. Mooren, 2004 .

Hormone replacement therapy and cardioprotection in the elderly

A. Pines, V. Mijatovic, M. J. Mooren, 1998, Journal of the Royal Society of Medicine.

Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women.

P. Kenemans, C. Netelenbos, C. Jakobs, 1998, Fertility and sterility.